Fiera Capital Corp Sells 14,334 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

Fiera Capital Corp decreased its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 3.0% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 466,075 shares of the company's stock after selling 14,334 shares during the period. Fiera Capital Corp owned 0.58% of Crinetics Pharmaceuticals worth $23,816,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Russell Investments Group Ltd. increased its holdings in shares of Crinetics Pharmaceuticals by 366,571.4% during the 1st quarter. Russell Investments Group Ltd. now owns 51,334 shares of the company's stock valued at $2,403,000 after acquiring an additional 51,320 shares during the last quarter. Swiss National Bank grew its holdings in Crinetics Pharmaceuticals by 21.4% in the 1st quarter. Swiss National Bank now owns 126,500 shares of the company's stock valued at $5,921,000 after buying an additional 22,300 shares during the last quarter. Vanguard Group Inc. grew its holdings in Crinetics Pharmaceuticals by 2.1% in the 1st quarter. Vanguard Group Inc. now owns 3,575,076 shares of the company's stock valued at $167,349,000 after buying an additional 72,624 shares during the last quarter. SG Americas Securities LLC grew its holdings in Crinetics Pharmaceuticals by 1,224.8% in the 2nd quarter. SG Americas Securities LLC now owns 79,051 shares of the company's stock valued at $3,541,000 after buying an additional 73,084 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in Crinetics Pharmaceuticals by 27.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,823,218 shares of the company's stock valued at $178,966,000 after buying an additional 814,360 shares during the last quarter. Institutional investors and hedge funds own 98.51% of the company's stock.

Crinetics Pharmaceuticals Price Performance

Shares of Crinetics Pharmaceuticals stock traded up $0.88 during midday trading on Friday, hitting $60.69. 573,323 shares of the company were exchanged, compared to its average volume of 787,043. Crinetics Pharmaceuticals, Inc. has a 52 week low of $25.75 and a 52 week high of $60.93. The firm has a 50 day simple moving average of $54.31 and a 200-day simple moving average of $50.70.

Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.08). The company had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.47 million. During the same period in the previous year, the business earned ($0.94) EPS. Crinetics Pharmaceuticals's revenue for the quarter was down 59.6% compared to the same quarter last year. On average, sell-side analysts forecast that Crinetics Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

Insider Activity at Crinetics Pharmaceuticals

In other news, insider Stephen F. Betz sold 1,035 shares of Crinetics Pharmaceuticals stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $51.50, for a total value of $53,302.50. Following the completion of the sale, the insider now directly owns 68,576 shares of the company's stock, valued at approximately $3,531,664. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Stephen F. Betz sold 3,000 shares of Crinetics Pharmaceuticals stock in a transaction on Monday, August 26th. The stock was sold at an average price of $53.19, for a total transaction of $159,570.00. Following the completion of the sale, the insider now directly owns 69,611 shares of the company's stock, valued at $3,702,609.09. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Stephen F. Betz sold 1,035 shares of Crinetics Pharmaceuticals stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $51.50, for a total value of $53,302.50. Following the sale, the insider now directly owns 68,576 shares of the company's stock, valued at approximately $3,531,664. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 43,410 shares of company stock valued at $2,275,929 in the last three months. Corporate insiders own 6.00% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on CRNX shares. Oppenheimer reaffirmed an "outperform" rating and issued a $73.00 target price (down previously from $74.00) on shares of Crinetics Pharmaceuticals in a report on Friday, August 9th. JMP Securities reiterated a "market outperform" rating and issued a $80.00 price objective on shares of Crinetics Pharmaceuticals in a research report on Friday, September 27th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $90.00 price objective on shares of Crinetics Pharmaceuticals in a research report on Monday, September 16th. Finally, HC Wainwright raised their price objective on Crinetics Pharmaceuticals from $60.00 to $69.00 and gave the stock a "buy" rating in a research report on Friday, August 9th. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $68.55.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.